Article
Biochemistry & Molecular Biology
Hongjiao Li, Chenglian Xie, Yurong Lu, Kaijing Chang, Feng Guan, Xiang Li
Summary: This study reveals that plasma exosomal miR92a is significantly upregulated in MDS/AML patients and can interfere with cell resistance to Ara-C by regulating the PTEN and Wnt/β-catenin signaling pathway.
Article
Biochemistry & Molecular Biology
Ashish Kumar Tripathi, Divya Rai, Priyanka Kothari, Pragati Kushwaha, Koneni Sashidhara, Ritu Trivedi
Summary: A compound, 4e, has been identified to have osteogenic potential in glucocorticoid induced osteoporosis (GIOP). Compound 4e preserved osteoblast differentiation and increased the expression of osteogenic genes, resulting in the preservation of bone microarchitecture and cortical thickness. This study is important for the treatment of glucocorticoid-induced osteoporosis.
Article
Multidisciplinary Sciences
Nanfang Huang, Yang Song, Wenhui Shi, Juan Guo, Lingyun Wu, Zheng Zhang, Qi He, Xiao Li, Feng Xu
Summary: DHX9 overexpression in myelodysplastic syndromes (MDS) is associated with poor prognosis and high risk of acute myeloid leukemia (AML) transformation. DHX9 is essential for malignant proliferation of leukemia cells. Suppression of DHX9 increases cell apoptosis and sensitizes cells to chemotherapy. Additionally, DHX9 knockdown inactivates PI3K-AKT and ATR-Chk1 signaling, promotes R-loop accumulation, and leads to R-loop-mediated DNA damage.
Article
Medicine, General & Internal
Alessia Campagna, Daniela De Benedittis, Luana Fianchi, Emilia Scalzulli, Lorenzo Rizzo, Pasquale Niscola, Anna Lina Piccioni, Ambra Di Veroli, Stefano Mancini, Nicoletta Villiva, Tiziano Martini, Sara Mohamed, Ida Carmosino, Marianna Criscuolo, Susanna Fenu, Maria Antonietta Aloe Spiriti, Francesco Buccisano, Marco Mancini, Agostino Tafuri, Massimo Breccia, Antonella Poloni, Roberto Latagliata
Summary: Patients with isolated del20q in myelodysplastic syndromes show distinct clinical and prognostic features, including older age, predominantly male, low bone marrow blast percentage, and lower platelet count. In terms of treatment, the majority receive erythropoiesis-stimulating agents, while a small portion progress to acute myeloid leukemia. The median overall survival is 60.6 months, with a 5-year cumulative survival rate of 55.9%.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Ning Guo, Yanling Yu, Yanru Chu, Qun Lou, Wei Huang, Liaowei Wu, Chenlu Fan, Mengyao Su, Meichen Zhang, Fanshuo Yin, Zhizhong Guan, Yanmei Yang, Yanhui Gao
Summary: In this study, it was found that miR-21-5p induced the activation of canonical Wnt signaling pathway by targeting PTEN and DKK2, providing important insights into the regulatory role of miR-21-5p in skeletal fluorosis.
Article
Medicine, Research & Experimental
Zhao Yan, Banjun Ruan, Shan Wang, Tianshu Du, Xiaolong Shao, Guo Chen, Li Wang, Dongsheng Zhai, Shu Zhu, Zifan Lu, Xiaorui Cao
Summary: This study investigates the role of QKI in bone formation and fat accumulation in mesenchymal stem cells (MSCs). The results show that QKI suppresses osteogenic differentiation of BMSCs by downregulating the expressions of Wnt5b, Fzd7, Dvl3, and β-catenin. Additionally, QKI deficient BMSCs transplantation may provide a new strategy for the treatment of orthopedic diseases such as osteoporosis.
ARCHIVES OF MEDICAL RESEARCH
(2023)
Article
Medicine, General & Internal
Calogero Vetro, Valeria Di Giacomo, Donato Mannina, Silvana Magrin, Antonio Mule, Maria Enza Mitra, Sergio Siragusa, Andrea Duminuco, Bruno Garibaldi, Maria Cristina Emanuela Vadala, Francesco Di Raimondo, Giuseppe A. Palumbo
Summary: This prospective observational study confirms the efficacy of erythropoietin zeta in the treatment of low-risk myelodysplastic syndrome. The results demonstrate a significant improvement in hemoglobin levels with the use of erythropoietin zeta.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Kathleen A. O'Leary, Debra E. Rugowski, Michael P. Shea, Ruth Sullivan, Amy R. Moser, Linda A. Schuler
Summary: Prolactin (PRL) collaborates with Apc(Min/+) to increase tumor incidence and modulate cancer stem cell activity through Notch-driven signals, shedding light on mechanisms whereby PRL elevates risk of breast cancer.
Article
Immunology
Yuxuan Li, Lutian Yao, Jing Lu
Summary: IL-35 inhibits adipogenesis by regulating the proliferation, cytotoxicity, and differentiation of adipocytes. It suppresses the expression of PPAR gamma and C/EBP alpha, and also influences the Wnt/beta-actin pathway through the regulation of Axin2 expression.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
Ana R. Moshkovsky, Marc W. Kirschner
Summary: Axin is a crucial protein in the canonical Wnt pathway, and its differential regulation allows for tissue-specific functions.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Endocrinology & Metabolism
Aohan Mei, Yini Peng, Xiaowei Liu, Zhengqian Chen, Yiye Zhang, Ruigang Zhu
Summary: This study established a rat model of intervertebral disc degeneration (IVDD) and investigated the effect of swimming exercise on IVDD rats. The results showed that swimming training could improve the damage and inflammation of degenerative intervertebral discs in rats, suggesting its positive application value in IVDD treatment.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
(2023)
Article
Gastroenterology & Hepatology
Hui Cheng, Qinfang Li
Summary: This study found that sevoflurane induces apoptosis and inhibits the growth, migration, and invasion of cholangiocarcinoma cells by inhibiting the Wnt/beta-catenin signaling pathway. It not only reveals the role of sevoflurane in the development of CCA but also elucidates new therapeutic agents for CCA.
BMC GASTROENTEROLOGY
(2023)
Article
Pathology
Xiaobo Nie, Haisheng Wang, Xiaoyun Wei, Lanqing Li, Ting Xue, Lili Fan, Han Ma, Yubing Xia, Yan-Dong Wang, Wei-Dong Chen
Summary: LRP5 is overexpressed in gastric cancer tissues and its expression is positively associated with advanced clinical stages and poor prognosis. Overexpression of LRP5 enhances proliferation, invasiveness, and drug resistance of gastric cancer cells through activating the canonical Wnt/β-catenin pathway and upregulating glycolysis. LRP5 and glycolysis-related genes also show a positive correlation in gastric cancer tissues.
AMERICAN JOURNAL OF PATHOLOGY
(2022)
Article
Environmental Sciences
Zhihao Lv, Hao Xu, Xuezhe Si, Shushuo Xu, Xinxiao Li, Ning Li, Qiang Zhou, Meiyu Chang, Sanqiao Yao, Haibin Li
Summary: Silicosis is an occupational lung disease caused by long-term inhalation of free silica dust. The Wnt signaling pathway has been found to be associated with the development of silicosis fibrosis, suggesting it as a potential target for treatment.
ENVIRONMENTAL TOXICOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Alexandre Vallee, Yves Lecarpentier, Jean-Noel Vallee
Summary: Glaucoma is a progressive neurodegenerative disease with oxidative stress, inflammation, and glutamatergic pathway playing key roles. CBD, a non-psychotomimetic phytocannabinoid, has shown potential therapeutic effects on glaucoma by increasing the WNT/beta-catenin pathway and reducing GSK-3 beta activity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Endocrinology & Metabolism
Aliya A. Khan, Mishaela R. Rubin, Peter Schwarz, Tamara Vokes, Dolores M. Shoback, Claudia Gagnon, Andrea Palermo, Claudio Marcocci, Bart L. Clarke, Lisa G. Abbott, Lorenz C. Hofbauer, Lynn Kohlmeier, Susanne Pihl, Xuebei An, Walter Frank Eng, Alden R. Smith, Jenny Ukena, Christopher T. Sibley, Aimee D. Shu, Lars Rejnmark
Summary: TransCon PTH demonstrated efficacy in maintaining normocalcemia and allowing independence from conventional therapy in individuals with hypoparathyroidism. The treatment also showed significant improvements in health-related quality of life and hypoparathyroidism-related symptoms.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Article
Oncology
Maher Hanoun, Leo Ruhnke, Michael Kramer, Christine Hanoun, Kerstin Schaefer-Eckart, Bjoern Steffen, Tim Sauer, Stefan W. Krause, Christoph Schliemann, Jan-Henrik Mikesch, Martin Kaufmann, Mathias Haenel, Edgar Jost, Tim H. Bruemmendorf, Lars Fransecky, Sabrina Kraus, Hermann Einsele, Dirk Niemann, Andreas Neubauer, Johannes Kullmer, Ruth Seggewiss-Bernhard, Martin Goerner, Gerhard Held, Ulrich Kaiser, Sebastian Scholl, Andreas Hochhaus, H. Christian Reinhardt, Uwe Platzbecker, Claudia D. Baldus, Carsten Mueller-Tidow, Martin Bornhaeuser, Hubert Serve, Christoph Roellig
Summary: This retrospective analysis of real-world data from the SAL-AML registry suggests that there is no significant benefit of high-dose cytarabine compared to intermediate dosages in consolidation therapy for AML patients under 65 years of age.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Song-Yau Wang, Tanja Holzhey, Simone Heyn, Thomas Zehrfeld, Susann Fricke, Franz Albert Hoffmann, Cornelia Becker, Leanthe Braunert, Thomas Edelmann, Inessa Paulenz, Marcus Hitzschke, Franziska Flade, Andreas Schwarzer, Klaus Fenchel, Georg-Nikolaus Franke, Vladan Vucinic, Madlen Jentzsch, Sebastian Schwind, Saskia Hell, Donata Backhaus, Thoralf Lange, Dietger Niederwieser, Markus Scholz, Uwe Platzbecker, Wolfram Poenisch
Summary: Autologous stem cell transplantation (ASCT) is the standard treatment for younger patients with newly diagnosed multiple myeloma (MM). However, many eligible patients are excluded from transplant studies due to restrictive exclusion criteria. This retrospective analysis included 540 MM patients who received ASCT between 1996 and 2019.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Hematology
Amer M. Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, Maximilian Stahl, Lionel Ades, Uma Borate, David Bowen, Rena Buckstein, Andrew Brunner, Hetty E. Carraway, Naval Daver, Maria Diez-Campelo, Theo de Witte, Amy E. DeZern, Fabio Efficace, Guillermo Garcia-Manero, Jacqueline S. Garcia, Ulrich Germing, Aristoteles Giagounidis, Elizabeth A. Griffiths, Robert P. Hasserjian, Eva Hellstrom-Lindberg, Marcelo Iastrebner, Rami Komrokji, Austin G. Kulasekararaj, Luca Malcovati, Yasushi Miyazaki, Olatoyosi Odenike, Valeria Santini, Guillermo Sanz, Phillip Scheinberg, Reinhard Stauder, Arjan A. van de Loosdrecht, Andrew H. Wei, Mikkael A. Sekeres, Pierre Fenaux
Summary: The initial response criteria developed by the International Working Group (IWG) in 2000 have limitations in their application to higher-risk MDS and their ability to fully capture the clinical benefits of novel investigational drugs. Therefore, an international panel of MDS experts used a modified Delphi process to develop consensus recommendations for updated response criteria that would be more reflective of patient-centered and clinically relevant outcomes. The updated criteria should lead to a better correlation between patient-centered outcomes and clinical trial results.
Article
Oncology
Rory M. Shallis, Naval G. Daver, Jessica K. Altman, Robert P. Hasserjian, Hagop M. Kantarjian, Uwe Platzbecker, Valeria Santini, Andrew H. Wei, David A. Sallman, Amer M. Zeidan
Summary: TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be classified under one term for their study in clinical trials, in order to simplify the screening processes and focus on treating patients based on their genetically defined disorders, rather than an arbitrary blast threshold.
Article
Hematology
Giulia Maggioni, Matteo Bersanelli, Erica Travaglino, Ana Alfonso Pierola, Annika Kasprzak, Arnan Sangerman Montserrat, Elisabetta Sauta, Claudia Sala, Tommaso Matteuzzi, Manja Meggendorfer, Matteo Gnocchi, Lin--Pierre Zhao, Cristina Astrid Tentori, Kathrin Nachtkamp, Daniele Dall'Olio, Ettore Mosca, Marta Ubezio, Alessia Campagna, Antonio Russo, Giulia Rivoli, Massimo Bernardi, Lorenza Borin, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Elena Saba, Saverio D'Amico, Luca Lanino, Benedetta Tinterri, Francesca Re, Marilena Bicchieri, Laura Giordano, Giovanni Angelotti, Pierandrea Morandini, Anne Sophie Kubasch, Francesco Passamonti, Alessandro Rambaldi, Victor Savevski, Armando Santoro, Arjan A. van de Loosdrecht, Alice Brogi, Valeria Santini, Shahram Kordasti, Guillermo Sanz, Francesc Sole, Norbert Gattermann, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Ulrich Germing, Maria Diez--Campelo, Matteo G. Della Porta
Summary: This study aimed to describe sex diversity in myelodysplastic syndromes and incorporate sex information into clinical decision-making. The study found differences between men and women in terms of disease genotype, phenotype, and clinical outcomes. Moreover, new prognostic models that included sex information were developed and performed better than the revised International Prognostic Scoring System.
LANCET HAEMATOLOGY
(2023)
Article
Engineering, Biomedical
Sofie Dragoun Kolibova, Eva Maria Woelfel, Haniyeh Hemmatian, Petar Milovanovic, Herbert Mushumba, Birgit Wulff, Maximilian Neidhardt, Klaus Pueschel, Antonio Virgilio Failla, Annegreet Vlug, Alexander Schlaefer, Benjamin Ondruschka, Michael Amling, Lorenz C. Hofbauer, Martina Rauner, Bjoern Busse, Katharina Jaehn-Rickert
Summary: Type 1 diabetes mellitus (T1DM) is associated with increased bone fragility. Our study found accelerated osteocyte apoptosis and local mineralization in T1DM patients, suggesting that T1DM speeds up bone aging and impairs its biomechanical competence. Dysfunction of the osteocyte network hampers bone remodeling and repair, contributing to the increased fracture risk in T1DM individuals.
ACTA BIOMATERIALIA
(2023)
Article
Hematology
Moshe Mittelman, Uwe Platzbecker, Sebastian Grosicki, Tomasz Lawniczek, Zewen Zhu, Dominik Selleslag
Summary: ASPIRE is a three-part international phase 2 trial that investigated the efficacy and safety of eltrombopag in patients with advanced myelodysplastic syndrome or acute myeloid leukemia and severe thrombocytopenia. The study found that approximately 30-65% of patients in the open-label extension phase experienced clinically relevant thrombocytopenic events. Long-term efficacy could not be determined due to the study design, and survival rates may be influenced by advanced disease. However, eltrombopag showed potential in treating thrombocytopenia in low-/intermediate-risk myelodysplastic syndrome patients, with consistent long-term safety results.
ACTA HAEMATOLOGICA
(2023)
Article
Endocrinology & Metabolism
Manuel Gado, Annett Heinrich, Denise Wiedersich, Katrin Sameith, Andreas Dahl, Vasileia I. Alexaki, Michael M. Swarbrick, Ulrike Baschant, Ingo Grafe, Nikolaos Perakakis, Stefan R. Bornstein, Martina Rauner, Lorenz C. Hofbauer, Holger Henneicke
Summary: This study demonstrates that activation of the sympathetic nervous system through cold exposure or selective I33-adrenergic receptor agonist can alleviate the adverse metabolic effects caused by chronic glucocorticoid exposure. Cold exposure preserves the function of brown adipose tissue and reverses white adipose tissue lipid accumulation, correcting obesity, hyperinsulinemia, and hyperglycemia caused by glucocorticoids.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
(2023)
Article
Medicine, General & Internal
Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, Amer M. Zeidan, Rami S. Komrokji, Jake Shortt, David Valcarcel, Anna Jonasova, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, Ana Carolina Giuseppi, Sandra Kreitz, Veronika Pozharskaya, Karen L. Keeperman, Shelonitda Rose, Jeevan K. Shetty, Sheida Hayati, Sadanand Vodala, Thomas Prebet, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Pierre Fenaux, Guillermo Garcia-Manero
Summary: In this study, we report the results of a prespecified interim analysis of luspatercept versus epoetin alfa for the treatment of anaemia due to lower-risk myelodysplastic syndromes. The results showed that luspatercept improved the rate of red blood cell transfusion independence and increased hemoglobin levels compared to epoetin alfa.
Letter
Hematology
Bettina Glatte, Kerstin Wenk, Anja Grahnert, Maik Friedrich, Maximilian Merz, Vladan Vucinic, Luise Fischer, Kristin Reiche, Miriam Alb, Michael Hudecek, Paul Franz, Stephan Fricke, Uwe Platzbecker, Ulrike Koehl, Ulrich Sack, Andreas Boldt, Sunna Hauschildt, Ronald Weiss
Article
Biophysics
Enrico Maffini, Maud Ngoya, Jacques-Emmanuel Galimard, Samia Harbi, Nicolaus Kroeger, Uwe Platzbecker, Henrik Sengeloev, Charles Craddock, Victoria Potter, Goda Choi, Patrice Chevallier, Friedrich Stolzel, Eleni Tholouli, Johan Maertens, Fabio Ciceri, Jan Cornelissen, Jaime Sanz, Alexandros Spyridonidis, Francesco Lanza, Arnon Nagler, Mohamad Mohty
Summary: Allogeneic HCT programs are becoming accessible for older AML patients. Patients aged ≥70 years who received HCT from matched sibling, unrelated, or haploidentical donors showed good clinical outcomes, with reduced relapse rates and improved leukemia-free survival in haploidentical and unrelated donor transplantations compared to matched sibling transplantation.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Oncology
Uwe Platzbecker, Valeria Santini, Rami S. Komrokji, Amer M. Zeidan, Guillermo Garcia-Manero, Rena Buckstein, Dimana Miteva, Karen Keeperman, Natalia Holot, Jose Alberto Nadal, Yinzhi Lai, Sadanand Vodala, Barbara Rosettani, Ana Carolina Giuseppi, Aylin Yucel, Pierre Fenaux
Article
Hematology
Srdan Verstovsek, Ruben Mesa, Vikas Gupta, David Lavie, Viviane Dubruille, Nathalie Cambier, Uwe Platzbecker, Marek Hus, Blanca Xicoy, Stephen T. Oh, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Aaron Gerds, Miklos Egyed, Jiri Mayer, Tomasz Sacha, Jun Kawashima, Marc Morris, Mei Huang, Claire Harrison
Summary: Momelotinib is a first-in-class inhibitor of Janus kinases 1 and 2, as well as activin A receptor type 1, and has shown efficacy in addressing the symptoms of myelofibrosis, such as splenomegaly, constitutional symptoms, and anemia. This long-term analysis of pooled data from three phase 3 studies demonstrated the safety and tolerability of momelotinib, with no evidence of long-term or cumulative toxicity. The most common adverse events were diarrhea and hematologic abnormalities, but they were generally manageable. This analysis provides valuable evidence supporting the use of momelotinib in the treatment of myelofibrosis.
Article
Medicine, Research & Experimental
Lorenz C. Hofbauer, Franziska Lademann, Martina Rauner
Summary: Osteocytes, senescent cells implicated in bone loss disorders, have been shown to be effectively cleared through systemic senolysis, preventing age-related bone loss and mitigating bone marrow adiposity. Cell-specific senolysis in osteocytes alone had only a partial effect. Surprisingly, transplantation of senescent fibroblasts into young mice led to osteocyte senescence and bone loss. These findings on osteocyte senescence and the effects of remote senolysis suggest potential strategies against multisystem aging.
JOURNAL OF CLINICAL INVESTIGATION
(2023)